Figure 11. The down-regulation of EGFR enhances sensitivity to anti-cancer drugs.

(A) Malme3M^R cells were transiently transfected with the indicated siRNA (each at 10 nM). At 24 h after transfection, cells were then with the indicated anti-cancer drugs for 24 h, followed by MTT assays. (B) Malme3M^R cells were transiently transfected with the indicated siRNA (10 nM). At 24 h after transfection, cells were then with taxol (1 μM), gefitinib (1 μM) or trastuzumab (10 μg/ml) for 24 h, followed by caspase-3 activity assays. Ttm denotes trastuzumab. **p < 0.005; ***p < 0.0005. (C) Same as (B) except that immunoblot analysis was performed. (D) Malme3M^R cells were transiently transfected with the indicated siRNA (each at 10 nM). At 48 h after transfection, cell lysates were subjected to immunoblot analysis (left panel). Malme3M^R cells were transiently transfected with the indicated siRNA (10 nM) along with the indicated construct (1 μg). At 48 h after transfection, immunoblot analysis was performed (right panel). (E) Malme3M^R cells were transiently transfected with the indicated siRNA (10 nM) along with the indicated construct (1 μg). At 24 h after transfection, cells were then treated with taxol (1 μM), gefitinib (1 μM) or trastuzumab (10 μg/ml) for 24 h, followed by caspase-3 activity assays. **p < 0.005.